Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs

Mehrdad Izadirad, Zoufang Huang, Farideh Jafari, Amir Ali Hamidieh, Ahmad Gharehbaghian, Yidong Li, Leila Jafari, Zhe‐Sheng ChenFrontiers in Cell and Developmental Biology 2021 · DOI

Abstract

Despite their small size, the membrane-bound particles named extracellular vesicles (EVs) seem to play an enormous role in the pathogenesis of acute leukemia. From oncogenic hematopoietic stem cells (HSCs) to become leukemic cells to alter the architecture of bone marrow (BM) microenvironment, EVs are critical components of leukemia development. As a carrier of essential molecules, especially a group of small non-coding RNAs known as miRNA, recently, EVs have attracted tremendous attention as a prognostic factor. Given the importance of miRNAs in the early stages of leukemogenesis and also their critical parts in the development of drug-resistant phenotype, it seems that the importance of EVs in the development of leukemia is more than what is expected. To be familiar with the clinical value of leukemia-derived EVs, this review aimed to briefly shed light on the biology of EVs and to discuss the role of EV-derived miRNAs in the development of acute myeloid leukemia and acute lymphoblastic leukemia. By elaborating the advances and challenges concerning the isolation of EVs, we discuss whether EVs could have a prognostic value in the clinical setting for leukemia.

Introduction: The Aggressive Nature of Acute Leukemia

Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) represent some of the most aggressive and heterogeneous forms of hematological malignancies. While initial chemotherapy can be effective, the high rate of relapse remains a significant clinical hurdle. This failure is often attributed to the complex "cross-talk" between leukemic cells and the bone marrow (BM) microenvironment. Understanding how leukemic cells manipulate their niche to survive and evade treatment is paramount. Central to this communication are Extracellular Vesicles (EVs)—tiny, membrane-bound messengers that act as "Trojan Horses," delivering oncogenic cargo to neighboring cells.

The Biology and Cargo of Extracellular Vesicles

EVs are categorized into three main types based on their size and biogenesis:

  1. Exosomes (30–150 nm): Derived from the endosomal pathway.
  2. Microvesicles (100–1,000 nm): Formed by direct outward budding of the plasma membrane.
  3. Apoptotic Bodies (50–5,000 nm): Released during programmed cell death.

These vesicles are not merely waste products; they are sophisticated delivery systems carrying a diverse array of proteins, lipids, and nucleic acids, particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs).

Common molecular cargo found in circulating extracellular vesicles.

As shown in the table above, EVs carry a wide variety of structural proteins, signaling molecules, and genetic material that can profoundly influence recipient cell behavior.

Mechanisms of Leukemogenesis and Niche Reprogramming

Leukemic cells utilize EVs to deliver oncogenic miRNAs into healthy hematopoietic stem cells (HSCs), effectively "reprogramming" them to halt normal differentiation and adopt leukemic characteristics. A prime example is the transfer of miR-155 in AML.

Mechanism of miR-155 transfer via EVs in AML cells leading to leukemia progression.

In AML, EVs transfer miR-155 to recipient cells, where it inhibits SHIP1, leading to the activation of the AKT signaling pathway. This cascade promotes cell survival and leukemia progression. Beyond direct cell transformation, EVs target Bone Marrow Stromal Cells (BMSCs). For instance, ALL-derived EVs containing miR-43a-5p can inhibit osteogenesis, creating a "leukemia-permissive" environment that favors tumor expansion over healthy hematopoiesis.

Furthermore, EVs facilitate the horizontal transfer of drug resistance. Chemo-resistant cells can package resistance-linked proteins (like MRP-1) or anti-apoptotic factors (like Bcl-2) into EVs, "gifting" these traits to sensitive cells and spreading resistance throughout the marrow.

Clinical Potential: Biomarkers and Monitoring

The molecular signature of EV cargo offers significant potential for non-invasive "liquid biopsies." Clinical studies have identified several high-impact correlations:

  • Prognostic Biomarkers: High exosomal levels of miR-10b and miR-532 in AML patients are associated with shorter overall survival and increased relapse risk.
  • Minimal Residual Disease (MRD): Genetic analysis of EVs has shown promise in detecting MRD in pediatric AML patients with higher sensitivity than some traditional methods.
  • CNS Involvement: In pediatric ALL, elevated EV-derived miR-181a serves as a potential biomarker for Central Nervous System involvement, potentially reducing the need for invasive lumbar punctures.

Challenges and Future Directions

Despite the promise, several technical "bottlenecks" must be addressed before EV-based diagnostics enter routine clinical use. The primary challenge is standardization. Current isolation methods, such as differential ultracentrifugation, size-exclusion chromatography (SEC), and polymer-facilitated precipitation, vary in terms of purity and yield. Overlapping size distributions between exosomes and microvesicles often lead to "noisy" data. Future work must focus on large-scale clinical validation and the development of standardized protocols to ensure reproducibility across different research and clinical settings.

Summary updated

Abstract

Despite their small size, the membrane-bound particles named extracellular vesicles (EVs) seem to play an enormous role in the pathogenesis of acute leukemia. From oncogenic hematopoietic stem cells (HSCs) to become leukemic cells to alter the architecture of bone marrow (BM) microenvironment, EVs are critical components of leukemia development. As a carrier of essential molecules, especially a group of small non-coding RNAs known as miRNA, recently, EVs have attracted tremendous attention as a prognostic factor. Given the importance of miRNAs in the early stages of leukemogenesis and also their critical parts in the development of drug-resistant phenotype, it seems that the importance of EVs in the development of leukemia is more than what is expected. To be familiar with the clinical value of leukemia-derived EVs, this review aimed to briefly shed light on the biology of EVs and to discuss the role of EV-derived miRNAs in the development of acute myeloid leukemia and acute lymphoblastic leukemia. By elaborating the advances and challenges concerning the isolation of EVs, we discuss whether EVs could have a prognostic value in the clinical setting for leukemia.
BibTeX
@inproceedings{izadirad2021extracellular,
  author = {Mehrdad Izadirad and Zoufang Huang and Farideh Jafari and Amir Ali Hamidieh and Ahmad Gharehbaghian and Yidong Li and Leila Jafari and Zhe‐Sheng Chen},
  title = {{Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.766371},
}
Figure